2018
DOI: 10.1136/bmj.k831
|View full text |Cite
|
Sign up to set email alerts
|

Affordability and availability of off-patent drugs in the United States—the case for importing from abroad: observational study

Abstract: ObjectivesTo evaluate whether off-patent prescription drugs at risk of sudden price increases or shortages in the United States are available from independent manufacturers approved in other well regulated settings around the world.DesignObservational study.SettingOff-patent drugs in the USA and approved by the Food and Drug Administration, up to 10 April 2017.Study cohortNovel tablet or capsule prescription drugs approved by the FDA since 1939 that were no longer protected by patents or other market exclusivi… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
17
0

Year Published

2019
2019
2022
2022

Publication Types

Select...
8

Relationship

3
5

Authors

Journals

citations
Cited by 16 publications
(17 citation statements)
references
References 17 publications
0
17
0
Order By: Relevance
“…1 For each ANDA, we also characterized the corresponding brand-name drug’s initial approval year, priority review status, Orphan Drug Act designation, World Health Organization essential medicine status, therapeutic area based on World Health Organization Anatomical Therapeutic Chemical code classification, and drug complexity, the latter using previously described methods. 2 We used descriptive statistics to characterize trends in recent generic drug approvals. We plotted quarterly trends from July 2016 to December 2018, including the proportion of ANDA approvals in each quarter (Q) that were drugs with limited competition and with prior drug shortage.…”
Section: Methodsmentioning
confidence: 99%
“…1 For each ANDA, we also characterized the corresponding brand-name drug’s initial approval year, priority review status, Orphan Drug Act designation, World Health Organization essential medicine status, therapeutic area based on World Health Organization Anatomical Therapeutic Chemical code classification, and drug complexity, the latter using previously described methods. 2 We used descriptive statistics to characterize trends in recent generic drug approvals. We plotted quarterly trends from July 2016 to December 2018, including the proportion of ANDA approvals in each quarter (Q) that were drugs with limited competition and with prior drug shortage.…”
Section: Methodsmentioning
confidence: 99%
“…Forty percent of generic medications without production competition in the United States had approved versions made by independent manufacturers outside of the United States, and importation could therefore help ensure lower prices. 7 …”
Section: The Certainty Of Uncertainty For a Global Supply Chainmentioning
confidence: 99%
“…16 In a study of nonprescription, generic oral forms approved by the US Food and Drug Administration (FDA) since 1939, only 19% had a manufacturer approved by four or more of seven non-US regulators evaluated. 17 Of the 26% of medications with no FDA-approved generic, only 48% were available from at least one manufacturer approved by one of the seven non-US regulators.…”
Section: Global Contextmentioning
confidence: 99%